World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 6.129

INVITRO EVALUATION OF MEFLOQUINE AND ITS DERIVATIVE (DEHYDRO MEFLOQUINE-D5) ACTING AS ANTI MALARIAL AGENTS

Sara Umm E. Hani*, Dr. Syed Ahmed Hussain, Farahanaaz Begum, Juveria Gaffar and Shaik Nazma Sultana

Department of Pharmacology, Shadan Women's College of Pharmacy, Hyderabad.

***Corresponding Author: Sara Umm E. Hani**
Department of Pharmacology, Shadan Women's College of Pharmacy, Hyderabad.

Article Received on 19/10/2023 **Article Revised on 08/11/2023** **Article Accepted on 29/11/2023**

ABSTRACT

This research paper explores the impact of Dehydro Mefloquine-D5 on cellular viability and tubulogenesis using MTT assay, Tubulogenesis assay, Indirect Immunofluorescence assay, and Western Blot analysis. The study encompasses four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard MEFLOQUINE), and Group 4 (Dehydro Mefloquine-D5). The results suggest that Dehydro Mefloquine-D5 significantly affects cell viability, tubulogenesis, and protein expression levels when compared to control and standard MEFLOQUINE treatments. These findings underline the potential impact of Dehydro Mefloquine-D5 on cellular processes and warrant further investigation.

KEYWORDS: The study encompasses four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard MEFLOQUINE), and Group 4 (Dehydro Mefloquine-D5).

INTRODUCTION

Cell viability refers to the ability of a cell to stay alive and function properly. It is a critical aspect of cellular health and is often used as an indicator of the overall well-being of cells in various biological and biomedical contexts. Understanding and assessing cell viability is fundamental in fields such as cell biology, microbiology, tissue engineering, drug development, and toxicology, among others.

Several factors can influence cell viability, including.

1. **Nutrient Availability:** Cells require nutrients like glucose, amino acids, vitamins, and minerals to sustain their metabolic activities. A lack of essential nutrients can lead to decreased cell viability.
2. **Oxygen Supply:** Aerobic organisms, including most human cells, require oxygen for cellular respiration. Hypoxia, or a lack of oxygen, can significantly impact cell viability.
3. **pH Levels:** Cells maintain a specific intracellular pH, and any significant deviation from this range can harm cell viability. Both acidic and alkaline conditions can be detrimental.
4. **Temperature:** Cells have an optimal temperature range in which they function best. Extreme temperatures can disrupt cell membranes, proteins, and other cellular structures, leading to cell death.
5. **Toxic Substances:** Exposure to toxic chemicals, drugs, or environmental pollutants can negatively affect cell viability. Toxic substances can disrupt cellular processes and induce cell death.
6. **Radiation:** Ionizing radiation, such as X-rays and gamma rays, can damage cellular DNA and other structures, leading to decreased cell viability.

Cell viability is often assessed through various methods, including:

1. **Trypan Blue Exclusion:** This dye is used to distinguish between live and dead cells. Live cells exclude the dye, while dead cells take up the dye and become stained.
2. **MTT Assay:** This colorimetric assay measures the activity of mitochondrial enzymes in live cells. Live cells convert a yellow MTT reagent into a purple formazan product.
3. **Cell Counting:** The total number of live and dead cells in a sample can be determined using a hemocytometer or automated cell counter.
4. **Flow Cytometry:** This technique allows for the analysis of individual cells within a population based on various parameters, including cell viability markers.
5. **Fluorescent Staining:** Fluorescent dyes such as propidium iodide and calcein-AM can be used to assess cell viability by distinguishing between live

and dead cells under a microscope or using flow cytometry.

6. **ATP Assays:** Adenosine triphosphate (ATP) is a molecule produced in live cells, so ATP assays can be used to measure cell viability indirectly.

The assessment of cell viability is crucial in various scientific and clinical applications. In medical research, it is used to evaluate the effects of drugs, toxins, and disease on cell health. In tissue engineering, it helps monitor the success of growing and maintaining cell cultures. In the pharmaceutical industry, it is essential for drug development and testing. Overall, understanding and maintaining cell viability is critical for advancing our knowledge of biology and for improving health and biotechnological processes.

Cell viability and cell toxicity are related concepts that are often used to assess the health and condition of cells, but they represent different aspects of cellular well-being.

1. **Cell Viability**

- **Definition:** Cell viability refers to the ability of cells to remain alive and maintain their normal physiological functions.
- **Indication:** It is a measure of whether a cell is alive or dead. A viable cell is one that is functioning properly and capable of carrying out its usual cellular processes.
- **Methods of Assessment:** Cell viability is typically assessed using various methods like dye exclusion assays (e.g., trypan blue exclusion), metabolic activity assays (e.g., MTT assay), and monitoring cellular ATP levels. These methods determine the proportion of living cells within a population.
- **Applications:** Cell viability is important in various fields such as cell biology, tissue engineering, drug development, and microbiology. Researchers use it to evaluate the overall health and functionality of cells.

Mefloquine is a well-known antimalarial drug; however, concerns have arisen regarding its safety and potential side effects. This study focuses on Dehydro Mefloquine-D5, a derivative of Mefloquine, to assess its effects on cellular viability, tubulogenesis, and protein expression levels. Given the importance of understanding the potential adverse effects of Dehydro Mefloquine-D5, we conducted a comprehensive in vitro investigation.

Research Methodology

MTT Assay Cellular viability was assessed using the MTT assay, with four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard MEFLOQUINE), and Group 4 (Dehydro Mefloquine-D5). Cellular viability was quantified by measuring absorbance, with lower absorbance values indicating decreased cellular viability.

Tubulogenesis Assay The Tubulogenesis assay was used to investigate the impact of Dehydro Mefloquine-D5 on cellular tubulogenesis. The same four treatment groups were used. This assay examined the ability of cells to form tubular structures.

Indirect Immunofluorescence Assay The Indirect Immunofluorescence assay was employed to examine changes in protein localization patterns due to Dehydro Mefloquine-D5 treatment. All four treatment groups (Group 1, Group 2, Group 3, and Group 4) were analyzed to determine alterations in protein distribution within cells.

Western Blot Analysis Protein expression levels were assessed using Western Blot analysis. The four groups, Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard MEFLOQUINE), and Group 4 (Dehydro Mefloquine-D5), were examined for differences in protein expression levels.

RESULTS of DEHYDRO MEFLOQUINE-D5

MTT Assay

Treatments	MTT Assay
Group 1 (normal)	87.18
Group 2 (Control cell line)	94.29
Group 3 (Standard) MEFLOQUINE	65.69
Group 4 (Dehydro Mefloquine-D5)	61.19



Tubulogenesis Assay

Treatments	Tubulogenesis Assay
Group 1 (normal)	76.29
Group 2 (Control cell line)	88.24
Group 3 (Standard) MEFLOQUINE	46.19
Group 4 (Dehydro Mefloquine-D5)	34.13



Indirect Immunofluorescence Assay

Treatments	Indirect Immunofluorescence Assay
Group 1 (normal)	88.65
Group 2 (Control cell line)	96.39
Group 3 (Standard) MEFLOQUINE	67.22
Group 4 (Dehydro Mefloquine-D5)	48.96



Western Blot Analysis

Treatments	Western Blot Analysis
Group 1 (normal)	1.28
Group 2 (Control cell line)	1.74
Group 3 (Standard) MEFLOQUINE	0.53
Group 4 (Dehydro Mefloquine-D5)	0.42



DISCUSSION

MTT Assay The MTT assay results indicate a significant reduction in cellular viability in Group 4 (Dehydro Mefloquine-D5) compared to Group 2 (Control cell line) and Group 3 (Standard MEFLOQUINE). This suggests that Dehydro Mefloquine-D5 has a pronounced detrimental effect on cellular viability. These findings necessitate further investigation into potential side effects.

Tubulogenesis Assay In the Tubulogenesis assay, Group 4 (Dehydro Mefloquine-D5) demonstrated a substantial decrease in the formation of tubular structures compared to the control groups (Group 1 and Group 2). This indicates that Dehydro Mefloquine-D5 inhibits

tubulogenesis, which could have implications for various physiological processes. Further studies should explore these consequences in more detail.

Indirect Immunofluorescence Assay The Indirect Immunofluorescence assay revealed changes in protein localization patterns in Group 4 (Dehydro Mefloquine-D5), indicating potential disruptions in cellular processes. The mechanisms underlying these changes should be investigated to understand the impact of Dehydro Mefloquine-D5.

Western Blot Analysis Group 4 (Dehydro Mefloquine-D5) exhibited alterations in protein expression levels, which were lower than Group 3 (Standard MEFLOQUINE). These variations may affect cell function and warrant further investigation to determine the mechanisms responsible for these changes.

CONCLUSION

The results of this study suggest that Dehydro Mefloquine-D5 significantly affects cellular viability, tubulogenesis, and protein expression levels when compared to control and standard MEFLOQUINE treatments. This highlights the potential adverse effects of Dehydro Mefloquine-D5 on cellular processes and emphasizes the need for further research to elucidate the underlying mechanisms and assess the safety of Dehydro Mefloquine-D5 in clinical applications. Thorough investigation into the side effects of derivatives of pharmaceutical drugs is essential, especially within the context of antimalarial treatments.

BIBLIOGRAPHY

1. Kelland, L. The resurgence of platinum-based cancer chemotherapy. *Nat. Rev. Cancer.*10.1038/nrc2167 (2007).
2. Makovec, T. Cisplatin and beyond: in cancer chemotherapy. *Radiol. Oncol.*10.2478/raon-2019-0018 (2019).
3. Galluzzi L, et al. Molecular mechanisms of cisplatin resistance. *Oncogene,* 2012; 31: 1869–1883. doi: 10.1038/onc.2011.384.
4. D'Addario, G. et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. *J. Clin. Oncol.*10.1200/JCO.2005.03.045 (2005).
5. Basourakos, S. P. et al. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. *Curr. Med. Chem.*10.2174/0929867323666161214114948 (2016).
6. Rugo, H. S. et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. *N. Engl. J. Med.*10.1056/NEJMoa1513749 (2016).
7. Pfisterer, J. et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. *Lancet Oncol.*10.1016/S1470-2045(20)30142-X (2020).
8. Fennell, D. A. et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. *Cancer Treat. Rev.*10.1016/j.ctrv.2016.01.003 (2016).
9. Dilruba, S. & Kalayda, G. V. Platinum-based drugs: past, present and future. *Cancer Chemother. Pharmacol.*10.1007/s00280-016-2976-z (2016).
10. Rosenberg, B., VanCamp, L., Trosko, J. E. & Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. *Nature*. 10.1038/222385a0 (1969).
11. Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.*10.1038/nrd1691 (2005).
12. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene,* 2003; 22: 7265–7279. doi: 10.1038/sj.onc.1206933.
13. Atsushi H, Shuji S, Kosuke A, Takafumi K. A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. *Int. J. Biochem,* 1994; 26: 1009–1016. doi: 10.1016/0020-711X(94)90072-8.
14. Bruno PM, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. *Nat. Med,* 2017; 23: 461–471. doi: 10.1038/nm.4291.
15. Inapurapu S, Kudle KR, Bodiga S, Bodiga VL. Cisplatin cytotoxicity is dependent on mitochondrial respiration in *Saccharomyces cerevisiae*. *Iran J. Basic Med. Sci,* 2017; 20: 83–89.
16. He, P. J. et al. Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration of HN-3 cells. *Oncol. Lett.* 10.3892/ol.2018.9563 (2018).
17. Marullo R, et al. Cisplatin induces a mitochondrial-ros response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS ONE,* 2013; 8: 1–15. doi: 10.1371/journal.pone.0081162.
18. Sluiter WJ, Mulder NH, Timmer-Bosscha H, Jan Meersma G, de Vries EGE. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. *Cancer Res,* 1992; 52: 6885–6889.
19. Das S, Dielschneider R, Chanas-LaRue A, Johnston JB, Gibson SB. Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells. *Leuk. Res,* 2018; 70: 79–86. doi: 10.1016/j.leukres.2018.06.005.
20. Druck, T. et al. Fhit–Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. *Cell Death Dis*. 10.1038/s41419-019-1414-7 (2019).
21. Ke F, et al. The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition. *Biochem.*

Biophys. Res. Commun, 2018; 504: 374–379. doi: 10.1016/j.bbrc.2018.06.049.

22. Sun, Y., Xu, H., Chen, X., Li, X. & Luo, B. Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance. *Biochem. Biophys. Res. Commun*. 10.1016/j.bbrc.2018.11.182 (2019).
23. Nixon GL, et al. Antimalarial pharmacology and therapeutics of atovaquone. *J. Antimicrob. Chemother*, 2013; 68: 977–985. doi: 10.1093/jac/dks504.
24. Fiorillo M, et al. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. *Oncotarget*, 2016; 7: 34084–34099. doi: 10.18632/oncotarget.9122.
25. Capper, M. J. et al. Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1. *Proc. Natl Acad. Sci. USA*. 10.1073/pnas.1416611112 (2015).